INTRODUCTION
T-cell based immunotherapy is becoming a hotspot of the cancer therapeutics area. Specifically, using gene transfer technologies, patient T-cells can be genetically modified to stably express single-chain variable fragments (scFv) or ligands capable of binding antigens or receptors, respectively, to confer novel major histocompatibility complex (MHC)-independent antigen specificities on tumor cells. These structures are called chimeric antigen receptors (CARs) and contain three basic elements-the extracellular antigen binding domain, transmembrane domain, and cytoplasmic signaling domain. First-generation CARs featured a single signaling domain most commonly derived from the CD3 component of TCR (T cell receptor)/CD3 complex. Second-or third-generation CARs were designed by including additional signaling domains, such as CD28 and/or 4-1BB, that potentiate T-cell effector functions and activate co-stimulatory pathways, resulting in upregulation of genes encoding anti-apoptotic proteins and increased cytokine secretion. With this strategy, a complete remission among 30 children and adults who received CD19-targeting CAR-T cell therapy for relapsed or refractory acute lymphoblastic leukemia (ALL) was achieved with 90% success rates (Porter et al., 2011, Davila and Brentjens, 2013; Grupp et al., 2013, Jensen and Riddell, 2014; Maude et al., , 2015 Pegram et al., 2014; Turtle, 2014; Condomines et al., 2015; Jonnalagadda et al., 2015) .
In solid tumor therapy, CAR-T cells showed little therapeutic efficacy for the following reasons: (i) off-target toxicity due to the expression of target antigens in normal tissue; (ii) heterogeneity of tumor lesions with the target-negative tumor cells ultimately becoming the dominant population, and most importantly; (iii) release of immune repressive cytokines, such as transforming growth factor (TGF)  and interleukin (IL) 10, by tumor cells, and presence of suppressive cells, such as regulatory T-cells (tregs) and tumor-associated macrophages (TAMs), etc., creating an immunosuppressive microenvironment encasing the tumor cells and significantly inhibiting CAR-T cell homing abilities (Kakarla and Gottschalk, 2014; Lamers et al., 2014; Abken, 2015; Hillerdal and Essand, 2015) . Accordingly, some research groups have engineered IL-12 co-expressed CAR-T-cells at the tumor foci to suppress the unfavorable tumor microenvironment. IL-12 is a heterodimeric inflammatory cytokine produced by activated antigen-presenting cells (APCs), neutrophils, and macrophages, that also induces Th1 CD4 + T-cell response. IL-12 can serve as signal 3, in concert with TCR activation (signal 1) and CD28 costimulation (signal 2) of CD8 + T-cells, resulting in optimized clonal expansion and effector function. IL-12 induces proliferation and cytotoxic activity of natural killer (NK) cells and generates anti-tumor activity through the effector cell-produced cytokines, including interferon-gamma (INF-), which in turn upregulate tumor cell Fas (CD95) and FasL. More significantly, IL-12 has been shown to modulate the hostile tumor microenvironment through multiple mechanisms, including reactivation of anergic tumor-infiltrated lymphocytes (TILs), inhibition of Treg-mediated suppression of the effector T-cells, recruitment of NK cells to the tumor site, and inhibition of TAM IL-10 and transforming growth factor- (TGF-) secretion (Chinnasamy et al., 2012; Chmielewski et al., 2014; Chmielewski and Abken, 2015; Pegram et al., 2015) .
Appropriate tumor targets need to be identified to minimize the off-target effect of CAR-T cells. Mucin 1 (MUC1) is becoming an interesting target in cancer immunotherapy, for three reasons. First, aberrant expression of MUC1 has been reported in most solid tumors and many hematologic malignancies (Kruger et al., 2000; Jonckheere and Van Seuningen, 2010) . Second, whereas MUC1 is normally confined to the luminal epithelium, this polarity of expression is lost upon malignant transformation. Third, glycosylation of MUC1 is largely deregulated in cancer. Owing to an altered glycosyltransferase expression, tumor-associated MUC1 is decorated by a preponderance of shorter glycans, including Thomsen-nouveau (Tn), sialyl Tn (STn), ThomsenFriedenreich (T), and sialyl-T (ST). Under-glycosylation of MUC1 unmasks cryptic epitopes within the extracellular domain containing a variable number of tandem repeats (VNTR), enabling tumor-selective binding by several antibodies (Abs) (Acres and Limacher, 2005; Yang et al., 2007; Beatson et al., 2010; Kimura and Finn, 2013; Madsen et al., 2013; Acres et al., 2015) . Some research groups recently reported their efforts in developing MUC1-CAR-T cells, in which SM3 scFv, a renowned antibody with tumor-associated MUC1 selectivity, was used for constructing CD28-CD3 CAR. However, the resultant SM3-CD28-CD3 CAR proved extremely poor in retargeting human T-cells toward a variety of MUC1-expressing tumor cells. These disappointing results illustrated the existence of two types of steric inhibition, one imposed by the large size of immobilized MUC1 and the other by its heterogeneous glycosylation. The precise binding properties of SM3 to tumor-associated MUC1 were then analyzed and found to be suboptimal. In particular, SM3 did not bind to MUC1-ST, which is widely expressed by many tumor cells. Another anti-MUC1 scFv, of HMFG2, was identified, differing from SM3 by five amino acids and exhibiting a 7.4-fold-higher affinity for unglycosylated MUC1, which was sufficient to enable T-cells grafted with this CAR to proliferate robustly when plated on anchored glycan-free MUC1. Accordingly, HMFG2-CD28-OX40-CD3z CAR was tested in a preclinical model, which resulted in a significant delay of tumor growth (Wilkie et al., 2008; Maher and Wilkie, 2009; Gheybi et al., 2014) .
No clinical trial has been reported to date for MUC1-targeting CAR-T therapy. Here, we present a case report from a first-in-human study of MUC1-specific CAR-T cells in a patient with MUC1-expressing seminal vesicle cancer. In order to reduce the off-target effect of CAR-T cells and overcome the immune suppressive microenvironment of tumor foci, we constructed two MUC1-CAR-T platforms. One platform comprised SM3-CD28-CD137-IL12 CAR (SM3-CAR), and the other pSM3-CD28-CD137 CAR (pSM3-CAR) with a mutated SM3 scFv sequence to improve SM3 binding to MUC1 ST glycans. In addition, we incorporated a novel strategy of CAR-T cell delivery, intratumoral injection. Consequently, we obtained clinical evidence of tumor responses with pSM3-CAR. Our data thus support the feasibility of pSM3-CAR-T cell approach, in combination with an interventional treatment, as a novel strategy for the treatment of patients with MUC1 + solid malignancies, and suggest therapeutic benefits of pSM3-CAR-T cells.
RESULTS

Preclinical analysis
One metastatic seminal vesicle cancer patient was enrolled in the trial. Before we recruited him into the program, biopsies from pleural and intraperitoneal metastases (cell smears and tissue sections) from this patient was stained for MUC1 expression. Notably, strong MUC1 expression was observed ( Figure 1A and B), more pronounced in the biopsy material than in MUC1-positive MCF7 control cells. To further verify MUC1 positivity, primary tumor cells were also assessed by western-blot and flow cytometry assays. Consistently, the tumor cells were also highly MUC1 positive ( Figure 1C and D) . Immunohistochemistry confirmed MUC1 expression in patient tumor biopsies (data not shown). We therefore concluded that, for this patient, MUC1 can be used as a CAR-T cell therapy antigen.
Anti-MUC1-CAR design
In general, the scFv fragment contributes to new antigen specificity of a CAR-T cell, whereas intracellular CAR signaling domains are responsible for the functional outcome of CAR-mediated T-cell activation. MUC1 is commonly over-expressed in tumors and it has been predicted to be a potential target of immune therapy in about 80% of all cancer cases (Acres and Limacher, 2005) . It is, however, also expressed in normal tissues, albeit as a different glycoform (Wilkie et al., 2008) . Accordingly, the scFv sequence for CAR construction had to be very carefully selected. MUC1-specific monoclonal antibodies (MAbs) distinguish healthy MUC1 from cancer-associated MUC1 (Kimura and Finn, 2013; Madsen et al., 2013) . This is supported by evidence from the Joyce Taylor-Papadimitriou laboratory, who showed in a series of excellent experiments that antibodies targeting the human milk fat protein mucin-1 chemically stripped of its carbohydrate side chains specifically reacted with the cancer-associated MUC1 glycoprotein (Gendler et al., 1991; Taylor-Papadimitriou et al., 1993) . This suggested that cancer associated MUC1 is non-or at least under-glycosylated in comparison with the normal MUC1 glycoprotein. Among the characterized MUC1 antibodies, clone SM3 is renowned for its selectivity against tumor-associated MUC1 (Granowska et al., 1990; Burchell and Taylor-Papadimitriou, 1993; Granowska et al., 1993; Wilkie et al., 2008) , we therefore first constructed SM3 scFv-based CAR with IL-12 co-expression (SM3-CAR). Because it has been reported that 4-1BB domain may enhance CAR-T cell persistence, our final version of SM3-CAR contained SM3 scFv fused to sequences derived from CD28, 4-1BB, and CD3, followed by an internal ribosome entry site (IRES)-controlled IL-12 sequence ( Figure  2A ). 
SM3 scfv mutation improves tumor-associated MUC1 binding capacity
Since SM3 scFv-derived CAR was extremely poor in retargeting human T-cells against a variety of MUC1-expressing tumor cells, we were concerned that our new SM3-CAR may lead to disappointing clinical outcomes regardless of the inclusion of IL-12. Recent studies by the Maher group suggested that scFv sequence cloned from HMFG2 hybridoma formed against MUC1 exhibited superior binding to tumor-associated MUC1, especially when the CAR comprised an IgD hinge fragment that provided greater flexibility and access to the epitope, thereby overcoming steric inhibition (Wilkie et al., 2008) . Based on these findings, we mutated six amino acids in the SM3 scFv sequence. The mutated form of SM3 scFv (pSM3 scFv) was fused to the Fc domain and IgD hinge fragment, and used to construct CD28-4-1BB-CD3 CAR (pSM3-CAR). This construct did not contain IL-12 ( Figure 2B ).
Characterization of MUC1-CAR-T cells
Lentiviral SM3-CAR and pSM3 particles were prepared as described in Materials and methods. Thirty MOI (multiplicity of infection) suspensions of SM3-CAR or pSM3-CAR lentiviruses, 110 8 mL 1 titers, were used to separately transduce the patient's T-cells. Flow cytometry assays indicated similar transduction efficiencies for the two CARs, and 21% and 18% of SM3-CAR-T-and pSM3-CAR-Tpositive cells, respectively, were observed (data not shown).
A series of in vitro immunology assays was used to further evaluate the constructs. Cytotoxicity assays were used to evaluate SM3-CAR-T cells against T47D cells, an endogenous MUC1-expressing tumor cell line (data not shown). Untransduced T cells and CD19-CAR lentiviral vector transduced T cells were served as negative control ( Figure 3A and B), which showed basic cytolytic activity toward T47D cells (15% and 21% respectively) with a E : T ratio (effector : target) of 30 : 1. In contrast, SM3-CAR-T cells and pSM3-CAR-T cells had greater cytolytic activity toward T47D cells. As shown in Figure 3C and D, when E : T ratio was 30 : 1, SM3-CAR-T and pSM3-CAR-T cells killed T47D cells up to 44% and 51% respectively.
Clinical antitumor response of MUC1-CAR-T cells
After SM3-CAR-T cells and pSM3-CAR-T cells were injected into two separate tumor lesions respectively and simultaneously as described in Materials and methods, we monitored the patient's responses as frequently as possible since we employed an interventional treatment strategy in this study. The patient began to suffer from mild headache, muscle pain, nasal congestion, and mild abdominal bloating discomfort, but with normal breath, blood pressure, pulse, and oxygen saturation, one day after the intratumoral injection. The patient's basal body temperature was 36.1°C before the initiation of CAR-T therapy, and increased to 38.2°C on third day post-injection, implying a positive response to the therapy ( Figure 4A ). From the sixth to twelfth day post the intratumoral injection, all discomforts disappeared and the body temperature returned to normal. However, started from 13 th day of post-intratumoral injection, patient experienced 1-3 times of loose stools daily for two days with a paste shape, although the stool color was normal. And at the 15 th day of post-intratumoral injection, there were blood found three times in the stools after the patient drinking cleaning fluid intestinal phosphate.
The patient's blood analysis indicated some abnormalities, including increased eosinophil ratio and counts, and elevated glucose levels (Table 1) , suggesting an inflammatory response, or an acute response. In comparison with the basal uric acid levels, which were within normal range (Table 1), the patient's uric acid levels post injection increased, implying a possible minor kidney dysfunction.
The patient was examined to evaluate the impact of CAR-T cell treatment on immune activation. This was accomplished by soluble immune-factor profiling of serum samples collected at defined time points. IL-6 and tumor necrosis factor alpha (TNF-) were determined, as well as CRP (C reaction protein), which has been reported to be associated with IL-6 expression . A transient cytokine release syndrome , with a 10 folds increase of IL-6 and ca. 60% increase of TNF- levels, was detected after intratumoral injection. The cytokines remained elevated for 21 d, until biopsies of the treated tumor were surgically analyzed. Larger increases of CRP levels were observed on the second and third day post-intratumoral injection, and remained elevated ( Figure 4B ). Although it is not clear from the cytokine data whether this effect was due to SM3-CAR-T cells or pSM3-CAR-T cells, at least some CAR-T cells triggered the patient's immune response.
To fully evaluate the therapeutic efficacy of CAR-T cells and determine if SM3-CAR-T or pSM3-CAR-T cells benefit the patient better, ultrasonographic images were taken at the 21st day of post-intratumoral injection, followed by a surgical resection of the tumors. Unfortunately, SM3-CAR-T tumor showed little necrosis (image data not shown), indicating that SM3-CAR-T cells failed to recognize tumor cells even IL-12 was co-expressed. In contrast, pSM3-CAR-T-treated tumor had two necrotic areas, including an old necrotic area, which might have been caused by a previous hypoxia, and a new necrotic area, which perfectly matched the sites of pSM3-CAR-T cell injections ( Figure 5 ). This indicated that mutating SM3 scFv may indeed have improved binding to tumor-associated MUC1 and, consequently, tumor cell killing.
Furthermore, tumor biopsies were analyzed by immunohistochemistry assay. As shown in Table 2 , SM3-CAR-T tumor and pSM3-CAR-T tumor both have infiltrated CD4 + T cells, as well as CD3 + /CD8 + T cells, suggesting the persistence of intratumorally injected T cells. Interestingly, one major difference between SM3-CAR-T tumor and pSM3-CAR-T tumor was positive TIA-1 expression in SM3-CAR-T tumor but not in pSM3-CAR-T tumor, which may be contributed by co-expression of IL-12 molecule in SM3-CAR-T tumor. Impressively, significant necrosis event was observed in pSM3-CAR-T tumor as shown in circled and arrowed upper left panel of Figure 6A . We also examined biopsies ( Figure 6D , E, K and L), demonstrating persistence of CAR-T cells, which was further supported by anti-Fc staining on frozen tissue sections ( Figure 6G and N) .
DISCUSSION
CAR-T cell immunotherapy has shown great antitumor potential in patients with hematologic malignancies in many trials, especially in ALL . However, antitumor effects of CAR-T cell approaches in solid malignancies were disappointing. This was, in part, due to off-tumor on-target toxicities, as has been observed in CAR-based clinical studies that have targeted carbonic anhydrase IX (CAIX), which is overexpressed in renal cell carcinoma but also expressed at low levels in normal tissues, including the liver (Lamers et al., 2013) . The first lethal case in CAR-T therapy involved a patient with colon cancer that has metastasized to the lungs and the liver and was refractory to multiple standard treatments. The patient with ERBB2 (receptor tyrosine-protein kinase erbB-2)-overexpressing tumors underwent a third-generation CAR therapy based on the widely used humanized mAb trastuzumab (herceptin). The patient received 10 10 CAR-T cells intravenously, but experienced respiratory distress within 15 min of the infusion, developed a dramatic pulmonary infiltrate (detected in chest X-ray image after 40 min of completion of the infusion), and died five days after treatment. It has been postulated that death resulted from the transfer of highly active anti-ErbB2-directed T-cells. Upon first-pass clearance in the lung, these cells recognized ErbB2 expressed by normal lung cells, and released inflammatory cytokines (including TNF- and IFN-) that caused pulmonary toxicity and edema. This was followed by a cascading cytokine storm and resulted in multi-organ failure, similar to the multiple organ dysfunction syndrome caused by a variety of acute physiological insults (e.g., trauma or severe infections) (Morgan et al., 2010) .
Another obstacle in CAR-T therapy of solid malignances is the immunosuppressive microenvironment created by tumor cells, which impairs the CAR-T cell homing ability. T-cell homing is an outcome of an as-yet incompletely understood interplay of a wide range of molecular interactions, and great efforts are invested to delineate the molecular mechanisms that underpin this phenomenon. The chemokine system may play a major part in driving T-cell migration and the expression of specific chemokine receptors can aid the precise trafficking of T-cells to tumors. Examples include co-expression of CXCR2 to encourage engineered T-cell migration towards melanoma (Lutschg et al., 2011) , and CCR2b expression for T-cell migration towards neuroblastoma (Craddock et al., 2010) . In addition, with respect to the immunosuppressive nature of the tumor milieu, TGF-, a candidate suppressive cytokine produced by tumor cells, represses the proliferation of both CD4 + and CD8 + CAR-T cell subsets but does not repress IFN- secretion of CAR-T cells or specific CAR-T cell cytolytic activity. CD28 co-stimulation overcomes the TGF--mediated repression of T-cell proliferation (Koehler et al., 2007) , reflected by a more pronounced killing of tumor cells. Furthermore, in a CD28-CD3 CAR, deletion of the lymphocyte-specific protein kinase (LCK) binding site in the CD28 endodomain could improve anti-tumor activity of the CAR-T cells even though Treg cells are present in the tumor lesion (Kofler et al., 2011) . Thus, CARs with the modified CD28 endodomain are expected to expedite the implementation of CAR-T cell therapy in patients whose tumors are heavily infiltrated by Tregs. CAR-T cell-mediated recruitment of other components of the immune system and their involvement in an antitumor response represent another key aspect of improving the therapeutic efficacy of CAR-T cells. Experiments with constructs comprising the CAR expression vector and a responsive cytokine gene expression-driving promoter have demonstrated that CAR-T cells can produce high levels of cytokines upon antigen binding. Indeed, studies have shown that therapy with CAR-T cells engineered to release IL-12 result in an enhanced recruitment of innate immune cells and reinforcement of their functions (Pegram et al., 2012; Chmielewski and Abken, 2015) . Notably, Chmielewski et al. showed that IL-12 secretion induced upon CAR engagement resulted in the destruction of antigen-negative cancer cells that would normally escape the T-cell therapy (Pegram et al., 2012; Chmielewski and Abken, 2015) . The above-mentioned reports indicate that Th1-driving cytokines, such as IL-12, can muster a macrophage response towards tumor cells that have ceased tumor antigen expression, in otherwise inaccessible tumor lesions, in a manner associated with a localized proinflammatory response and reduced systemic toxicity. It is important to identify whether other cytokines or immune-potentiating molecules can strengthen and fine-tune the overall patient immune response towards solid tumors, thereby amplifying the antitumor effect driven by the CAR-T cells and to establish an immunological memory to challenge recurrence of the tumor.
Given the above-mentioned reasons, it is critical to consider potential off-target toxicities and strategies that mitigate these toxicities in the early clinical developments of CAR-T cell solid malignancies approaches. Here, we have shown the feasibility of employing CAR-T cells using a mutated anti-MUC1 scFv (pSM3) construct based on SM3 sequence. We have explored the safety and bioactivity of MUC1-redirected CAR-T cells in a patient with advanced seminal vesicle carcinoma. MUC1 is a well-established tumor associated antigen (TAA), which is abnormally expressed in a variety of cancer cells, predominantly epithelial tumors (Jonckheere and Van Seuningen, 2010) . MUC1 is commonly over-expressed in tumor-associated form that has been predicted to be a potential target of immune therapy for about 80% of all cancer cases (Kimura and Finn, 2013) . It is also expressed in normal tissues (Peat et al., 1992) , albeit as a different glycoform. It is noteworthy that the first detailed report of T-cell response to MUC1 in humans was very unusual in that the T-cells were not specific to MUC1 peptide sequences within the target surface MHC I (Barnd et al., 1989) . Rather, they were MHC I-unrestricted and were specifically blocked by SM3 antibody raised against MUC1 protein core. Therefore, we chose SM3 scFv sequence as our initial candidate for constructing CAR-T cells. However, a previous report indicated that SM3 binding to tumor-associated glycoforms of MUC1 was inadequate (Wilkie et al., 2008) . Therefore, Wilkie et al. developed a modified scFv construct that improved the retargeting capacity of tumor-associated MUC1-specific CAR (Wilkie et al., 2008) . We mutated six amino acids in the SM3 scFv sequence to mimic HMFG2, and with further optimization, we obtained an artificial scFv sequence of pSM3. Our findings show that the safety of pSM3-CAR-T cells was acceptable for intratumoral delivery, by injection, and mediated antitumor activity in vivo, including the induction of epitope spreading. We detected evidence of antitumor activity despite no pretreatment lymphodepletion. Meanwhile, although SM3-CAR-T cells showed cytotoxicity toward T47D cells in vitro, they failed to kill the patient's tumor cells in vivo even though IL-12 was artificially co-expressed with SM3-CAR. This suggested that the scFv element plays a vital role in CAR-T cell therapy.
We designed two types of CAR-T constructs to evaluate the safety and efficacy of CAR-T cells. One, SM3-CAR, was predicted to bind tumor-associated MUC1 poorly, but the constructed cell line co-expressed IL-12. We hypothesized that IL-12 would play a major role against tumor cells if the engineered CAR-T cells would not be able to fully recognize their tumor target. The other CAR, pSM3-CAR, comprised a mutated SM3 scFv sequence to improve its binding to tumor-associated MUC1 in the absence of engineered IL-12 co-expression. This experimental approach was designed to demonstrate the role of tumor antigen targeting in a cancer patient treatment. We observed little therapeutic benefits when using SM3-CAR-T cells, but an obvious anti-tumor activity exerted by pSM3-CAR-T cells, suggesting that a careful choice of the target antigen, and the appreciation of its accessibility and expression levels, must be considered in future proposals of CAR-T cell clinical trials.
However, target antigen selection and CAR-T cell intratumoral injection constitute only the first step toward treatment and cure of solid tumors. Considerable challenges still remain for CAR-T cell therapy. For example, given the long timeline of tumorigenesis, most solid tumors are invariably less oxygenated than normal tissues from which they arose. This so-called tumor hypoxia leads to resistance to radiotherapy and anticancer chemotherapy, as well as predisposes to increased tumor metastases (Dhani et al., 2015) . Accordingly, even though CAR-T cells are injected intratumorally, tumor hypoxia is expected to affect CAR-T cell viability, which in turn will seriously reduce their therapeutic efficacy. As part of a solution to this problem, we are developing new strategies, such as normalizing blood supply to the tumor prior to CAR-T cell injection.
Development of immunotherapy against MUC1 raises two additional concerns. First, MUC1 is expressed at lower levels by several normal tissues. Nonetheless, this did not interfere in Ab-based therapeutic protocols targeting this antigen (Taylor-Papadimitriou et al., 2002; Beatson et al., 2010; Kimura and Finn, 2013) . Cells of a non-tumorigenic mammary cell line were not killed by CAR-T cells despite low-level expression of MUC1, according to another report. This may reflect the predominance of core two glycans on MUC1 in non-transformed cells (Dalziel et al., 2001; Mungul et al., 2004; Tarp et al., 2007; Blixt et al., 2011; Beatson et al., 2015) that inhibit HMFG2 binding (Wilkie et al., 2008) . Together, these reports are reassuring when considering clinical risks posed by MUC1-targeting T-cells. A second concern of Ab-based immunotherapy comprises reduced efficacy due to binding of soluble antigen targets. The polyvalent nature of MUC1 raises the probability that Ab binding might produce large circulating immune complexes, leading to immunopathology. However, binding of soluble MUC1 may favor the CAR-based approach, facilitating tumor-dependent T-cell expansion and persistence. Such a mechanism has been implicated in the in vivo efficacy of CAR-grafted T-cells against B-cell tumors (Correa et al., 2003) . We did not detect any apparent evidence of off-tumor toxicities accompanying the CAR-T cell dosage or intratumoral delivery used in our study, although blood was found in the patient's stools after the patient consumed cleansing intestinal phosphate fluid. This suggested that the mutated SM3 scFv sequence (pSM3 scFv) provides a safer approach targeting cancer-associated MUC1.
Some interesting pathological observations were made during this trial. First, the treated tumor biopsies were predominantly infiltrated with the CD8 + T-cells, with fewer CD4 + T-cells. Increasing evidence supports the existence of elevated Treg numbers in solid tumors and hematologic malignancies. Tregs, first identified by Sakaguchi (Sakaguchi et al., 2006) , mediate peripheral tolerance to self and innocuous environmental antigens. Originally characterized as CD4 + CD25 + lymphocytes, they also express the forkhead/winged helix family transcription factor FoxP3. This is critical for both the development of Tregs and for their suppressive capacities, and, to an extent, has enabled improved characterization of these cells (Oleinika et al., 2013) . Since we used the aAPC (artificial antigen presenting cells) approach to prepare CAR-T cells, which resulted in CD8 + -dominated CAR-T cells, the observation of few CD4 + T-cells and numerous CD8
+ T-cells in the biopsies suggested that the infiltrating T-cells were CAR-T cells, which was further supported by immunostaining with Fc antibody (data not shown). Second, we found one major difference between biomarker expression by SM3-CAR-T-treated tumor and pSM3-CAR-T-treated tumor, namely, the former was TIA-1 positive while the latter was TIA-1 negative. TIA-1 is an intracellular cytotoxic lymphocyte protein that is localized within cytoplasmic granules containing serine proteases. It is a 15-kD-granule membrane-associated protein that can induce apoptotic cell death when introduced into permeabilized cells (Gross et al., 2001) . Anti-TIA-1 MAbs detect a subpopulation of CD8 + T-and NK cells that have cytotoxic activity. Our observation could be partially explained by contributions of IL-12 to TIA-1 expression, since we induced IL-12 expression in SM3-CAR-T-treated tumor and IL-12 may recruit and activate NK cells and repel anergic TILs.
Overall, our findings of tumor necrosis induced by pSM3-CAR-T cells have significant implications for the role of CAR therapy in treating MUC1 positive carcinomas. The clinical activity, intervention treatment strategy, and an improved scFv-targeting of tumor-associated MUC1 suggest that CAR-T cell therapy is a promising treatment modality for patients with solid malignancies.
MATERIALS AND METHODS
Patient background
Patient#2 had an advanced left seminal vesicle cancer with extensive metastasis, and was enrolled into a clinical trial at the Suzhou Kowloon Hospital with the approval of The Ethics Committee of the Hospital. Written informed consent was obtained before the trial. This patient was first diagnosed with left seminal vesicle cancer in 2006.
The last spiral CT scan of this patient was performed on February 25, 2015, and included chest, abdomen, and pelvis. When compared to an earlier CT scan from October 6, 2014, the sizes of most metastatic lesions increased, some were unchanged, and some decreased. In the increased size lesions, the right upper lobe pleural implant increased from 2.11.2 cm 2 to 3.41.8 cm 2
. Dated pleural implant seen in the right paravertebral region increased from 1.9 to 2.4 cm. An implant seen in the right lower lobe increased from 1.2 to 1.9 cm. Pleural nodularity involving the right major fissure was also more prominent when compared to the earlier CT scan.
The metastatic lesions whose sizes decreased included left supraclavicular lymph node that was measured as 2.51.9 cm 2 , compared with 2.92.2 cm 2 in the earlier CT scan, and an implant on the right middle lobe minimally decreased in size from 1.5 to 1.4 cm. . A metastatic lesion adjacent to the left renal hilum increased from 1.41.3 cm 2 to 2.01.6 cm 2 . Some of the metastatic lesions were stable, e.g. one lesion adjacent to the right kidney measuring 1.81.3 cm 2 . The patient's spleen was resected. Overall, no significant change was observed in the appearance of the dilated bile duct system. Some atrophy of the left kidney was detected, but no bilateral hydronephrosis was found. Surgical changes of colorectal anastomosis in the pelvic region were apparent, with no overall significant change in soft tissue mass in the prostatic bed region.
Clinical protocols
Phase I clinical trial (NCT02587689) was designed to evaluate the manufacturing feasibility and safety of MUC1-CAR-T cells in patient with advanced seminal vesicle carcinoma. The patient received two intratumoral injections of SM3-CAR-T and pSM3-CAR-T cells into two separate tumor lesions respectively, where one mass has a size of 38.1 mm×23.7 mm located at right upper outer quadrant and another lesion is of 33.6 mm×22.8 mm located at inferior the xiphoid process region, demonstrated by axial CT (Figure S1 in Supporting Information). Both lesions received a dosage of 5×10 5 CAR-T cells, followed by serum cytokines monitoring. 21 d later after completing this treatment, grayscale ultrasound analysis and immunohistochemistry assays were performed to evaluate the clinical response.
MUC1-CAR construction
MUC1-CAR expression cassettes were designed as described in the RESULTS. Briefly, SM3-CAR and pSM3-CAR expressing a single chain antibody of SM3, and a mutated single chain antibody of SM3 (pSM3) were constructed, with T cell activation signal, costimulatory signal, with IL-12 in SM3-CAR, or without IL-12 in pSM3-CAR. The lentiviral vector plasmid of pCDH-CMV-MCS-EF1-CopGFP was used as a gene transfer backbone vector.
T cell culture 20 mL of peripheral blood mononuclear cells (PBMC) were separated from patient blood using Ficoll (GE ) and suspended at a concentration of 1×10 6 cells per mL in T cell medium. T cells were cultured on 24-well plates with the density of 1×10 6 cells per well and stimulated by pAPC CTL Kit (PersonGen Biomedicne (Suzhou) Co., Ltd, Suzhou). Briefly, on day 1 (one day after transduction by lentiviruses), the T cells were stimulated with -irradiated aAPCs at a 1 : 2 T cell/aAPC ratio. aAPCs were added on day 7 during expansion. 100 IU mL 1 of IL-2 (Novoprotein) alone or combined with 30 ng mL 1 IL-21 (IL-21; eBioscience, Inc., USA) were added to the cultures every 48 h beginning on day 7. CAR-T cells were cultured for 12 d, and viable cells were counted on the basis of trypan blue exclusion. T cells that were not genetically modified were used as control T cells; these cells were propagated on g-irradiated aAPCs as well.
Lentivirus production
The packaging cells of 293T were maintained in 10% fetal bovine serum, 1% penicillin/streptomycin, and 1% nonessential amino acids in DMEM (Hyclone ) at 37C with 5% CO2. The packaging plasmids were R, Rev, and VSV-G. Replication-defective lentiviral particles pseudotyped with VSV-G envelope were produced by transient transfection of 293T cells with 10 mg of the gene transfer constructs, 6.5 mg of R, 3.5 mg of VSV-G and 2.5 mg of Rev, using transfection reagents. The transfection medium was replaced after 12 h with fresh culture medium. Viral supernatants were harvested at 72 h after transfection and filtered through 0.22 mm filters. Supernatants were either used immediately for transductions or were aliquoted and stored at 80°C until use. Titers of viral supernatants were determined by transducing 293T cells with serial dilutions of viral supernatants, followed by flow cytometry analysis of Fc-positive cells, 48 h after transduction.
Lentiviral transduction
To determine transduction efficiency, T cells were used to transduce with lentivirus harvested from 293T cell transfection. T cells (5×10 5 ) were counted, placed in wells of 24-well plates, and inoculated with lentiviral supernatants above (MOI=30). The transduced cells were incubated at 37°C for 4-6 h, and then the supernatants were removed and replaced with 2 mL volume of fresh 10% RPMI-1640 medium (Hyclone, GE Healthcare Bio-Sciences, USA). At 72 h post-transduction, T cells were performed Fc immunostaining and observed by fluorescence microscope qualitatively and analyzed by FACSCalibur (BD Biosciences, USA).
CAR detection on transduced T cells
Transduced T cells were analyzed using FACSCalibur (BD) to determine the Fc-positive cell ratio. Cells were washed and suspended in phosphate-buffered saline (PBS), and subjected to flow cytometry assay.
Cytotoxicity assay T47D tumor cell line (purchased from ATCC) that is highly expressing endogenous MUC1 were labeled with CFSE (carboxyfluorescein succinimidyl ester, BD). CFSE-loaded T47D cells were mixed with SM3-CAR-T cells and pSM3-CAR-T cells respectively at a ratio of 5 : 1 and 30 : 1, and incubated for 24 h. Untransduced T cells were served as negative controls. After 24 h of co-culture, cells were stained with 7-AAD (7-aminoactinomycin D, BD), and the percentage of dead tumor cells (CFSE positive and 7-AAD positive) was determined. Co., Ltd. Fengtao You, Licui Jiang, Yunhui Zong, Lei Huang, Man Lu, Jirong Tang, Yafen Li, Sisi Ye, Dan Chen are employees of Persongen Biomdicine (Suzhou) Co., Ltd.
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